Inflazyme Pharmaceuticals (T.IZP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sean Janzen who wrote (1169)	2/10/1999 8:56:00 AM
From: Chuca Marsh	Read Replies (1) of 1501

Congrats IZP: Full Text is out seperatly- 60 Days Study Period/ Right of First Refusal on Others: biz.yahoo.com Under the agreement, Inflazyme will be free to develop additional IPL576 derived compounds for any inflammatory indication other than asthma or respiratory disease. Hoechst Marion Roussel will have the right of first refusal to license those additional products on commercial terms to be agreed upon. The two companies are working toward the completion of a definitive agreement within 60 days, which will then be subject to approval by U.S. and Canadian regulatory authorities. A joint research and development committee of Inflazyme and Hoechst ...>> Chuca

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next